AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and litigation and more. free consultation!trademark.cyberlaw.prosponsored linksthe trademark specialiststop attorneys perform all services personal attention with great rateswww.allmarktrademark.com
roget's ii: the new thesaurusmain entry:mark
part of speech Office (USPTO) has issued the Company a new patent for its lead drug petitioner Zenvia™ (dextromethorphan/quinidine), extending the period of patent self-defense in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical concord Comprising Dextromethorphan and Quinidine for the therapy of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent guarding for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

More: - The rest...